| Wednesday, May 19, 2010 | ||
| 07:00:00 | Registration and Morning Coffee | |
| 08:25:00 | Toxicology | |
| 08:30:00 | Chairperson’s Opening Remarks | |
| 08:40:00 | OPENING KEYNOTE PRESENTATION - Revealing the “Magic” of Monoclonal Antibodies | Joy Cavagnaro |
| 09:10:00 | Recommendations for Nonclinical PK Comparability Study Designs for Monoclonal Antibodies | Wendy Putnam |
| 09:40:00 | The Role of Pharmacokinetics in the Design, Conduct and Interpretation of Toxicology Studies with Antibody-Based Biotherapeutics | Stanley A. Roberts |
| 10:10:00 | Coffee Break, Poster and Exhibit Viewing | |
| 11:05:00 | Tox - Safety | |
| 11:10:00 | Nonclinical Reproductive and Developmental Toxicity Testing Strategies with Antibody Therapeutics | William J. Breslin |
| 11:40:00 | Translational Safety for Therapeutic Antibodies: Protecting Subjects and Enabling Risk:Benefit Decisions During Early Clinical Development | Andrew Erdman |
| 12:10:00 | Luncheon Presentations (Sponsorship Opportunities Available) or Lunch on Your Own | |
| 13:25:00 | Tox - Testing Models | |
| 13:30:00 | Chairperson’s Remarks | |
| 13:35:00 | Species Selection: The Foundation of the Nonclinical Toxicology Program | Marque Todd |
| 14:05:00 | Surrogates: Their Use, Qualification and Challenges | Janet Clarke |
| 14:35:00 | Real Time Cell Surface Interaction Analysis: A Focus on Lectin-Cell Glycan Interactions | Julien Saint-Guirons |
| 15:05:00 | Networking Refreshment Break, Poster and Exhibit Viewing | |
| 15:50:00 | Problem Solving Break-Out Sessions | |
| 16:10:00 | Table 1: Toxicologists & Clinicians – We’re Talking, But Are We Communicating? | Meredith Rocca |
| 16:25:00 | Table 2: Cross Species Specificity – The Challenge Faced When Characterizing Targets | Shane Olwill |
| 16:40:00 | Table 3: Data Integration – Do You Need to Work Across Silos? | Jeffrey A. Engelhardt |
| 16:50:00 | Networking Cocktail Reception in the Exhibit Hall | |
| 18:00:00 | End of Day | |
| Thursday, May 20, 2010 | ||
| 08:00:00 | Registration and Morning Coffee | |
| 08:25:00 | Novel Therapies In Development | |
| 08:30:00 | Chairperson’s Opening Remarks | |
| 08:35:00 | Targeting GPCRs with Therapeutic Antibodies | Hai Yan |
| 09:05:00 | Fsn0503: A Novel Cathepsin S Specific Antibody that Blocks Angiogenesis and Tumor Invasion | Shane Olwill |
| 09:35:00 | Development of Antibody Drug Conjugates: An Emerging Class of Drugs | Carmel Lynch |
| 10:05:00 | Coffee Break, Poster and Exhibit Viewing | |
| 11:00:00 | Pre-Clinical Strategies | |
| 11:05:00 | Nonclinical Regulatory Strategy and Interacting with Regulators | Jeffrey A. Engelhardt |
| 11:35:00 | Nonclinical Dosing Strategies to Support First-in-Human (FIH) Clinical Studies | Meredith Rocca |
| 12:05:00 | End of Conference | |
How We Rank